InflaRx N.V Cash Flow Conversion Efficiency
InflaRx N.V cash flow conversion efficiency. Based on the latest financial reports, InflaRx N.V (IF0) has a cash flow conversion efficiency ratio of -0.113x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.71 Million ≈ $-5.50 Million USD) by net assets (€41.56 Million ≈ $48.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of InflaRx N.V (2016–2025)
Cash flow conversion efficiency of InflaRx N.V from 2016 to 2025. This chart illustrates how InflaRx N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IF0 share price today for real-time trading data and today's change.
InflaRx N.V Cash Flow Conversion Ratio Explained
InflaRx N.V cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
InflaRx N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InflaRx N.V ranked by their cash flow conversion efficiency. Also see IF0 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UBM Development AG
VI:UBS
|
0.009x |
|
Shanghai Waigaoqiao Free Trade Zone Group Co Ltd B
SHG:900912
|
0.021x |
|
Argent
JSE:ART
|
0.099x |
|
Reit Azorim HF Living Ltd
TA:AZRT
|
-0.016x |
|
CASH CONVERTERS INTL
F:UKC
|
N/A |
|
Norstar
TA:NSTR
|
0.024x |
|
Grammer AG
XETRA:GMM
|
-0.141x |
|
Lake Superior Acquisition Corp. Class A Ordinary Shares
NASDAQ:LKSP
|
0.000x |
Annual Cash Flow Conversion Efficiency for InflaRx N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of InflaRx N.V from 2016 to 2025. Review IF0 financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €41.56 Million ≈ $48.58 Million |
€-35.31 Million ≈ $-41.29 Million |
-0.850x | -7.48% |
| 2024-12-31 | €61.42 Million ≈ $71.80 Million |
€-48.56 Million ≈ $-56.77 Million |
-0.791x | -114.48% |
| 2023-12-31 | €102.58 Million ≈ $119.93 Million |
€-37.81 Million ≈ $-44.21 Million |
-0.369x | +3.49% |
| 2022-12-31 | €88.35 Million ≈ $103.29 Million |
€-33.74 Million ≈ $-39.45 Million |
-0.382x | -0.68% |
| 2021-12-31 | €105.28 Million ≈ $123.08 Million |
€-39.94 Million ≈ $-46.69 Million |
-0.379x | +19.14% |
| 2020-12-31 | €77.86 Million ≈ $91.03 Million |
€-36.53 Million ≈ $-42.70 Million |
-0.469x | -16.34% |
| 2019-12-31 | €107.15 Million ≈ $125.27 Million |
€-43.20 Million ≈ $-50.51 Million |
-0.403x | -183.28% |
| 2018-12-31 | €151.39 Million ≈ $176.99 Million |
€-21.55 Million ≈ $-25.19 Million |
-0.142x | -39.89% |
| 2017-12-31 | €119.43 Million ≈ $139.63 Million |
€-12.15 Million ≈ $-14.21 Million |
-0.102x | -152.36% |
| 2016-12-31 | €-25.69 Million ≈ $-30.03 Million |
€-4.99 Million ≈ $-5.84 Million |
0.194x | -- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more